Contact the Editorial Desk

Editorial correspondence

Peptide Battery welcomes correspondence on the research record: a citation quoted inaccurately, a newly published study on epitalon or MOTS-c, or a regulatory update that changes an approval or scheduling status. This class of correction — one that improves the accuracy or currency of the digest — is the most useful message this desk receives, and each one is read and considered directly.

The most actionable submissions specify: the page in question, the exact passage being corrected or challenged, and the supporting reference — a DOI or PubMed identifier wherever possible. That format allows a proposed change to be checked against its source before it is acted on.

Editorial mailbox: editors@peptidebattery.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Peptide Battery is a literature digest, not a clinical service or product vendor, so it cannot:

• Advise on, recommend, or comment on human use of epitalon, MOTS-c, or any other peptide.
• Suggest a dose, cycling schedule, or route of administration for any individual.
• Evaluate whether a cell-culture, animal-model, or observational finding applies to a specific person's situation.
• Sell, source, recommend, or help locate either compound from any supplier.
• Advise athletes subject to anti-doping rules, given that MOTS-c intersects with WADA/USADA monitoring.

Epitalon and MOTS-c are both unapproved research chemicals; readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.